Clinical Trial Update: Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating an explorative co-formulation of insulin degludec with insulin aspart versus separate formulations and versus biphasic insulin aspart 3…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Biphasic insulin aspart 30 (insulin aspart, biphasic 30/70)
• NovoLog (insulin aspart) (insulin aspart)
• Tresiba (insulin degludec) (insulin degludec)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 1 | Phase 1 | Status: COMPLETED